Numerous studies have demonstrated that tight glycaemic control reduces long-term complications in both Type 1 and Type 2 diabetes. However, current intensive insulin regimens increase the risk of hypoglycaemia, dissuading many attempting this approach. Normal physiological insulin profiles consist of a stable, basal component and meal-related surges in secretion. Conventional insulin regimens cannot mimic this profile accurately due to pharmacokinetic limitations. Human insulin has a slow onset of action, thus patients are advised to inject about 30 min before a meal, ensuring peak insulin concentrations coincide with postprandial glucose excursions. This is clearly impractical for many and can lead to pre-meal hypoglycaemia if the meal is delayed. Furthermore, it only partially overcomes the unphysiological insulin profile and patients experience postprandial hyperglycaemia and are vulnerable to postabsorptive hypoglycaemia. Insulin aspart and insulin lispro are rapid-acting analogues that allow a more physiological replacement of mealtime insulin secretion. They reduce postprandial glucose and usefully reduce the incidence of hypoglycaemia when used in a basal-bolus regimen in tightly controlled patients. Pre-mixed insulins, containing a combination of rapid-acting and intermediate-acting insulin, are widely used, particularly in Type 2 diabetes. They have limitations achieving tight glucose targets but early data suggest that the combination of 30% insulin aspart and 70% protaminated insulin aspart may also reduce severe hypoglycaemia. On-going clinical trials will establish whether they can be used to achieve better glycaemic control with less hypoglycaemia.
Hypoglycaemia in insulin-treated diabetes
Hypoglycaemia is the most feared adverse consequence of insulin therapy. Severe hypoglycaemia, which may be associated with incapacity, injury or seizures, is particularly unwelcome in the elderly who also have a high probability of significant atherosclerotic disease.
Clinical studies indicate that conventional insulin therapy in those with Type 1 diabetes results in severe hypoglycaemic episodes in approximately 10 -30% of patients per year. In the DCCT study of Type 1 diabetes, patients in the control arm receiving one to two insulin injections per day had a 10% risk of severe hypoglycaemia per year. 1 Although the frequency of severe hypoglycaemia appears to be lower in insulin-treated patients with Type 2 diabetes than in those with Type 1 diabetes, data from the UKPDS indicate that it remains a limiting factor in sustaining tight glycaemic targets. In this study involving newly diagnosed patients with Type 2 diabetes, symptomatic hypoglycaemia was reported in over 70% of those assigned to insulin, with major hypoglycaemic episodes requiring third party assistance or hospitalisation occurring in 11% of patients over 6 y. 2 Preliminary data from a community based study including Type 2 diabetic patients treated with insulin for clinical reasons (and presumably later in the course of the disease than the UKPDS cohorts) suggest that the prevalence of severe hypoglycaemia in late Type 2 diabetes approaches that of Type 1. 3 Tight glycaemic control improves diabetic prognosis but increases the risk for hypoglycaemia Strict control of blood glucose (HbA 1C < 7%) can prevent the onset and slow the progression of long-term complications in both Type 1 and Type 2 diabetes. 4, 5 In the DCCT study, intensified insulin treatment reduced the incidence of late diabetic complications and delayed the progression of existing complications compared to conventional regimens. 4 However, intensified insulin therapy was associated with a greater risk of hypoglycaemia. 6 The incidence of severe episodes of hypoglycaemia in the intensive arm of the DCCT was about three times the rate seen with standard therapy, with severe episodes occurring in about 30% of patients. 1 In the UKPDS study of Type 2 diabetes, tight glycaemic control usually involving insulin therapy also reduced the risk of progression of microvascular disease but, as in the DCCT study, at the expense of a greater risk of hypoglycaemia. Results from both the DCCT and UKPDS demonstrated that there is no threshold value for HbA 1C below which further risk reductions cannot be achieved with improved control, particularly for cardiovascular disease. Thus, current treatment regimens that achieve tight glycaemic control reduce the long-term misery of diabetic complications at the expense of the short-term embarrassment and potential danger of hypoglycaemia.
Hypoglycaemic unawareness
For many insulin-treated patients, treatment-related hypoglycaemia, or fear of it, is a major factor preventing them from achieving normoglycaemia. While much hypoglycaemia is symptomatic and inconvenient rather than dangerous to the patient, a proportion of patients with insulin-treated diabetes fail to recognise a falling blood glucose, in a syndrome of hypoglycaemic unawareness, in which patients do not recognise imminent hypoglycaemia until it is too late to be corrected. The condition is aggravated by tight glycaemic control, longstanding disease, and increased episodes of mild, even symptomless, hypoglycaemia. Unawareness, in some degree, is estimated to affect up to 25% of all patients with Type 1 diabetes, with the proportion increasing to 50% in patients who have had diabetes for over 20 y. 7, 8 Those with hypoglycaemic unawareness are more prone to suffer severe hypoglycaemia, particularly if they maintain strict glycaemic control. Estimates suggest that patients with partial or complete unawareness are seven times more likely to experience severe episodes than those who retain their awareness. 9 However, strategies that involve preventing all episodes of hypoglycaemia can restore awareness, sometimes within a few weeks. 10, 11 Although the physiological defects that accompany the syndrome usually improve, they do not return to normal. 12 
Physiology of insulin secretion
The increased risk of hypoglycaemia associated with trying to maintain near-normoglycaemia during insulin therapy, reflects the inability of exogenous insulin regimens to reproduce physiological insulin profiles. Normal insulin secretion consists of two major components: a chronic basal release plus meal related surges in secretion. 13 The role of the lowlevel basal insulin secretion is to modulate the rate of overnight hepatic glucose production and glucose output between meals. Thus basal glucose levels are maintained within a narrow range. Meal-related insulin secretion controls postprandial increases in blood glucose, which seldom rise above 5.5 mmol=l for more than 30 min. 14 
Insulin replacement therapy
The aim of insulin therapy is to mimic normal insulin patterns. Ideal insulin replacement should therefore be capable of reproducing both the basal and prandial= postprandial secretion profile to achieve 24-hour a day glycaemic control. The latest strategies are known as basalbolus therapy, since they attempt to reproduce both the basal and meal-induced components of normal insulin secretion.
Unfortunately, no combination of conventional insulin preparations accurately simulates normal insulin secretion. Pharmacokinetic profiles of human insulin preparations have major limitations. Following subcutaneous administration, soluble human insulin is only gradually absorbed into the systemic circulation, resulting in a slow onset of action. Because of the length of time it takes to reach peak concentrations, patients are usually advised to inject soluble insulin about 30 min before a meal to try to ensure that its maximum concentration coincides with the hyperglycaemic peak following food intake. This is inconvenient for patients and may lead to pre-meal hypoglycaemia if the meal is delayed. Furthermore, the strategy has only limited effectiveness. The duration of action of regular insulin is considerably longer than the physiological postprandial insulin peak. Thus, conventional insulin delivery results in relative postprandial hypoinsulinaemia and postabsorptive hyperinsulinaemia, which lead to postprandial hyperglycaemia and a high risk of postabsorptive hypoglycaemia, especially at night.
Due to the high concentrations required to maintain conventional human insulin in vials and cartridges, insulin molecules tend to associate into hexamers before and immediately following subcutaneous administration. Absorption into the systemic circulation is limited by the dissociation time of hexamers into dimeric and monomeric insulin units and typically the plasma kinetic profile produced by injection of soluble human insulin (HI) shows a significant delay before insulin appears. Plasma concentrations increase reaching a peak after 1 -2 h, followed by a slow decline returning to baseline levels within 6 -8 h. 15 However, recent advances in protein engineering through recombinant DNA technology have produced insulin analogues with properties that have significantly advanced insulin replacement therapy.
Insulin analogues
Two rapid-acting insulin analogues, insulin aspart and insulin lispro, have been developed that have absorption profiles allowing for a more physiological replacement of mealtime insulin secretion. Substitutions or minimal alterations in the amino acid sequence relative to human insulin have produced insulin molecules with a reduced tendency to selfassociate, increasing their absorption rate following subcutaneous injection. The rapid onset of action of these insulins means that they can be administered immediately before meals and their shorter duration of action and perhaps reduced intra-individual variability have the potential to reduce the risk of hypoglycaemia.
Insulin aspart [B28 Asp]-human insulin has a similar affinity for the insulin receptor and metabolic potency as HI. 16 Pharmacological studies have demonstrated that insulin aspart is rapidly absorbed into the blood after subcutaneous injection, resulting in a faster onset of action and shorter duration of action than HI. 17 -19 Peak plasma insulin concentrations are achieved in approximately half the time needed for HI (between 30 to 50 min), while C max values are typically more than twice those of HI. 17 -19 In clinical studies in patients with Type 1 diabetes, insulin aspart modestly but consistently reduced postprandial glucose excursions to a greater extent than regular human insulin, 18,20 -22 reducing the risk of severe hypoglycaemia in some studies, 20 particularly at night. 23 In two large, longterm prospective studies of multiple injection therapy, home blood glucose monitoring demonstrated lower postprandial glucose measurements, while the incidence of nocturnal hypoglycaemia was reduced. 21, 22 In the study by Home et al, the incidence of nocturnal major hypoglycaemic events was 8% in patients on insulin aspart compared to 11% in patients on HI, giving a relative risk of 0.70 (95% CI, 0.47; 1.04) (P ¼ 0.076). 22 Comparable data from the study by Raskin et al gave an incidence of 4% for patients on insulin aspart vs 8% for patients on HI (RR, 0.50 [95% CI 0.29; 0.86], P ¼ 0.013). 21 The failure to achieve more than a small, albeit statistically significant, reduction in HbA 1C in these two studies may relate to the absence of a suitable basal insulin replacement strategy at the time the studies were run.
The greatest reductions in rates of hypoglycaemia have been demonstrated in smaller scale studies, particularly where glycaemic control has been tight. Significantly fewer severe hypoglycaemic events occurred during treatment with insulin aspart than with HI (20 vs 44, P < 0.002) in a crossover study of 90 men with Type 1 diabetes, in addition to a smoother 24-hour glucose profile and lower postprandial glucose values. 20 Another double-blind, randomised, crossover study in 155 patients with Type 1 diabetes compared rates of hypoglycaemia and overall glycaemic control in a basal-bolus setting comparing insulin aspart and soluble HI. 23 Insulin aspart or HI was injected 0 -5 min before meals, and NPH was injected as basal insulin once-or twice-daily as required. Insulin aspart reduced the rate of severe nocturnal (24:00 -06:00) hypoglycaemia by 72% compared with regular HI (Figure 1 ). The rate of mild hypoglycaemic events was reduced by 7% with insulin aspart compared with HI (P < 0.05) (Figure 1 ). There was also a trend towards lower overall rates of severe hypoglycaemia (insulin aspart, 0.87 vs HI, 1.16 episodes per patient per year) and higher daytime rates (insulin aspart, 0.65 vs HI, 0.43 episodes per patient per year) with insulin aspart although neither difference was statistically significant. The reductions in hypoglycaemia were achieved with maintained glycaemic control. Mean HbA 1C (%, mean AE s.d.) was similar at the end of the treatment period between treatment groups (insulin aspart 7.7 AE 0.8 vs HI 7.7 AE 0.9) (Figure 2 ). 23 Insulin pre-mixes While basal-bolus therapy using the rapid-acting insulin analogues is the most logical way of trying to maintain the best glycaemic control, the patient is encumbered with multiple daily injections and the need for frequent blood glucose monitoring. It is not surprising that many patients elect for a simpler insulin regimen, despite its limitations. For those who prefer diabetes to intrude as little as possible in their day-to-day lives, regimens using mixtures of short and intermediate acting insulins, ready mixed in the bottle or vial, have offered a tempting solution, reducing the number of daily injections while partly addressing both prandial and basal insulin requirements. These ''off the shelf'' mixes have been termed 'pre-mixes'.
Traditional pre-mixes contain 30% free HI and 70% NPH insulin and are injected twice daily, before breakfast and the evening meal. However, because of the slow absorption of human soluble insulin and the peaked profile of NPH, they provide only a crude approximation of the physiological profile of prandial and basal insulin requirements. Their injection, 30 min in advance of meals is still recommended. 
Reducing hypoglycaemia with insulin analogues S Heller
Pre-mixes containing rapid-acting insulin analogues in place of the soluble HI, can, however, be injected at mealtimes and should provide improved control of postprandial blood glucose, at least for the meal immediately after the injection. Ideally they should be injected prior to each main meal to give an immediate prandial burst of insulin, followed by a slow sustained rise provided by the slower acting component. However, it has not been possible to find a single premix ratio that can be injected three times daily to meet postprandial needs and still provide adequate basal insulin requirements. However, in view of the reductions in hypoglycaemia observed with regimens including rapid-acting analogues, twice-daily pre-mix regimens containing a rapid-acting insulin analogue injected at breakfast and suppertime might offer some advantages over conventional premix insulins. It seems worthwhile investigating whether they might provide better or equivalent glycaemic control for patients unable or unwilling to undertake the intensive demands of basal-bolus therapy, while reducing the risk of treatment-related hypoglycaemia.
In biphasic insulin aspart (BiAsp 30), insulin aspart is administered as a mix of 30% soluble (free) molecules and 70% protaminated (crystallised) molecules. Analogues cannot be combined with NPH insulin, as used in traditional pre-mixes, because the transfer of protamine between molecules will result in unpredictable kinetics. Transfer of protamine groups between insulin molecules in BiAsp 30 is of no consequence because the ratio of free and protaminated insulin aspart molecules remains constant.
Clinical and pharmacological studies have confirmed the ability of BiAsp 30 to address basal and postprandial insulin requirements as a twice-daily insulin and there are data indicating that it has the potential to reduce the risk of hypoglycaemia. In a pharmacokinetic study by Jacobsen et al, BiAsp 30 was shown to be more rapidly absorbed and to produce greater peak serum concentration than BHI 30, 24 confirming the effect of insulin aspart within the pre-mixed preparation. The area under the concentration-time curve (AUC) for insulin over the first 90 minutes was significantly greater for BiAsp 30 than for BHI 30 (1403 vs 752 mU=l.min, P < 0.001) and the mean maximum insulin concentration (C max ) was higher for BiAsp 30 than for BHI 30 (23.4 vs 15.5 mU=l, P < 0.0001) with C max being achieved far quicker for BiAsp 30 than for BHI 30 (60 vs 110 min, P ¼ 0.0001). The AUC insulin 6 -24 h was similar between treatments indicating similar pharmacokinetic properties of the protaminated portions of both insulins. In a second study, BiAsp 30 was shown to have a faster onset of glucose-lowering activity together with an improved potency over the first 4 hours compared to BHI 30. The duration of action of the intermediate-acting fraction of both insulins was similar. 25 The superior kinetic profile of BiAsp 30 in comparison to BHI 30 seen in the pharmacokinetic and pharmacodynamic studies has been confirmed in multiple dose studies of patients with diabetes. In clinical studies, BiAsp 30 has been shown to provide improved postprandial glycaemic control compared to BHI 30 without increasing the risk of hypoglycaemia. In an open-label, randomised, parallel group comparison, 294 insulin-treated patients with either Type 1 or Type 2 diabetes were randomised to receive BiAsp 30, injected in the 10 min preceding breakfast and dinner, or BHI 30 injected 30 min prior to breakfast and dinner. 26 Treatment continued for 12 weeks, with dose adjustments made as required based on the results of home blood glucose monitoring.
Significantly lower blood glucose concentrations were demonstrated following BiAsp 30 than following BHI 30 after breakfast and dinner, before lunch and at bedtime (Figure 3 ) although in the absence of an injection before lunch there was unsurprisingly no difference in post-lunch glucose values.
There were also modest but significant effects on postprandial glucose control with BiAsp 30 when analysed on the basis of mean prandial blood glucose increment (post-meal minus pre-meal blood glucose) over the three meals including lunch. After 12 weeks, mean prandial increment was 1.52 AE 2.07 mmol=l in the BiAsp 30 group vs 2.33 AE 2.31 mmol=l for BHI 30, equivalent to a 40% reduction in mean prandial increment with BiAsp 30 compared to a 12% reduction with BHI 30 (between-treatment difference, P ¼ 0.01). HbA 1C was comparable between the two groups, suggesting that in a pre-mix regimen without a lunchtime insulin dose, an analogue pre-mix may have useful advantages over conventional HI pre-mixes. In addition, there was some indication that BiAsp 30 might help to reduce the risk of hypoglycaemia.
Overall, half as many episodes of major hypoglycaemic events were reported in the BiAsp 30 group compared to the BHI 30 group and a trend towards a lower rate of minor hypoglycaemic events was demonstrated. In total, 20 major episodes were reported by 8% of patients in the BiAsp 30 group, and 42 major events were reported by 12% of patients in the BHI 30 group, giving a relative risk (RR) of major Promising results regarding the reduction in hypoglycaemic events with BiAsp 30 compared to BHI 30 have also been demonstrated in a 24-month extension of the above study. 27 Of the 125 patients with Type 2 diabetes (BiAsp 30 n ¼ 58; BHI 30 n ¼ 67) who elected to continue treatment, 95 patients (76%) completed the 2-year treatment period. The overall frequency of both major and minor hypoglycaemic episodes was lower in the BiAsp 30 group than in the BHI 30 group, and decreased during the study, perhaps reflecting an improved understanding of the use of the insulins by the patients and their carers (Figure 4) . During the first year, four major episodes were reported in the BiAsp 30 group compared to 11 major episodes in the BHI 30 group. In the second year, equivalent incidences were 0 events and 8 events, respectively. Minor episodes also tended to be less frequent in the BiAsp 30 group than in the BHI 30 group, especially during the second year.
The suggestion that pre-mixed insulin containing rapidacting insulin analogues has the potential to reduce hypoglycaemia needs to be confirmed in an adequately powered study. A further randomised, multicentre, crossover study is now being conducted to test the hypothesis directly. It is comparing the effects of BiAsp 30 and BHI 30 on the rate of hypoglycaemic events in insulin-treated patients with Type 2 diabetes, and is designed to evaluate 128 patients over a 40 week study period, during which patients will receive 16 weeks of treatment with each insulin pre-mix. The primary endpoint is to determine the frequency of hypoglycaemic episodes, measured by a continuous glucose monitoring system (CGMS, MiniMed), over 3 days, at 8 week intervals (visits 2, 4, 6, 8 and 10) with levels of < 3.5 mmol=l classed as hypoglycaemia.
Conclusions
In summary, large-scale, prospective outcome studies have unequivocally demonstrated the pivotal role of tight glycaemic control achieved with intensive antidiabetic therapy in reducing the development or deterioration of diabetic morbidity and its probable role in increasing life expectancy. 4, 5 However, the cost of improved glycaemic control and intensive therapy is an increased risk of hypoglycaemia.
The apparently close association between tight glycaemic control and an increased risk of hypoglycaemia results from the limitations of conventional subcutaneous insulin therapy and its inability to reproduce the physiology of the betacell. Studies with insulin analogues in a basal-bolus regimen have convincingly demonstrated their ability to reduce hypoglycaemia in patients with Type 1 diabetes, particularly at night. The greatest benefit appears to be derived in those patients with the tightest glycaemic control. Recent data also indicate that pre-mixed insulin, comprised of a mixture of rapid-and intermediate-acting insulin analogues, may also have the potential to reduce the risk of hypoglycaemia in patients with Type 2 diabetes.
